NuCana plc (NCNA) Stock Price & Analysis
NuCana plc (NCNA) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $0.7181 (-13.77%), as of the Nov 19, 2026 trading session; market cap $2.99M.
Educational signal · not a buy or sell recommendation · How to read this
NuCana plc · NCNA · NASDAQ
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments using its proprietary ProTide technology.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · NuCana (NCNA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and a fragile balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Slipping.
- EPS beat 7 of the last 8 reports
- Altman Z -14.96 · Piotroski F 2
- ROE -51.0% · ROA -44.9% · current ratio 5.15
Holding back: balance-sheet strain, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 31 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.7181 | |
| Change on the day | -13.77% | |
| 52-week range | $0.7181 – $4.55 | |
| Market capitalisation | $2.99M | — |
| Shares traded on the day | 111.0K |
Price & events
Other perspectives
Council score for NuCana (NCNA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is NuCana (NCNA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. NuCana plc (NCNA) is listed on NASDAQ. It employs 11 people and is led by Hugh Stephen Griffith. The market values it at $2.99M.
What do the latest results show for NuCana (NCNA)?
Short answer · as of
Against analyst estimates the company has EPS beat 7 of the last 8 reports.
What are the financial strengths and risks for NuCana (NCNA)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -14.96 · Piotroski F 2. Trailing ratios: ROE -51.0% · ROA -44.9% · current ratio 5.15.
Data-derived red flags
- Listing risk — at $0.7181 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -14.96 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-51.0%) — the business is not currently generating profit on shareholder capital.
What should you watch next at NuCana (NCNA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $3.44M · EPS -8.01 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for NCNA.
Checked against the records this page reads, on the dates shown above.
How does NuCana compare with its peers?
Short answer
NuCana's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| NuCana (NCNA) — this page | $0.7181 | $2.99M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $3.44M
- EPS estimate
- $-8.01
Measured against a quoted price of $0.7181 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NCNA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NCNA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NCNA
These answers are editorial: 1 of these 9 answers is drawn from the NCNA research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NCNA?
NCNA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is NCNA a good stock to buy?
Stock Expert AI does not rate NCNA buy, sell or hold. NuCana plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NCNA stock price today?
The last price recorded for NuCana plc (NCNA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for NCNA?
The main risks for NuCana plc include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. The company's financial resources are limited, and it may need to raise additional funding, which could dilute existing shareholders. Patent expiration and generic competition also pose a threat. As an ADR, NCNA is subject to currency risk.
What are the key factors to evaluate for NCNA?
NuCana plc (NCNA) holds a MoonshotScore in the low range. The company's lead product candidate, Acelarin, is in Phase III clinical trial for the treatment of patients with pancreatic cancer. Not financial advice.
How frequently does NCNA data refresh on this page?
NCNA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NCNA's recent stock price performance?
NuCana plc (NCNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary ProTide technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NCNA overvalued or undervalued right now?
NuCana plc (NCNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NCNA before investing?
Before investing in NuCana plc (NCNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 4 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com